Nielk
Senior Member
- Messages
- 6,970
Jennie Spotila of OccupyCFS - http://www.occupycfs.com/2013/12/16/iom-panelists-balance-experts-information-bias/
excerpt:
The overall panel balance is 53% known and 47% unknown to the ME/CFS community. None of us think this is sufficient, but we do not agree on what the right split would be. Some of us think the panel should be 100% ME/CFS experts; others think the addition of at least one or two more experts would be appropriate.
Mary Dimmock has raised a very important point: in order to judge whether this panel is adequate, we have to think about the task. If this panel is going to create a case definition for the broader set of conditions that meet the various CFS criteria, then some might make the argument that this panel is appropriate. But if the panel is focused on the disease we described to the FDA in April, then Mary concludes that the panel needs more, and a broader cross-section, of ME/CFS experts and fewer psychologists. As Mary has reported, HHS and IOM have been vague in detailing which disease group is the focus of the panel.
We’re faced with a chicken-egg dilemma: identifying the disease focus should happen prior to the panel selection, but instead we have a panel with a seemingly vague task focus. This panel composition seems to hold a middle ground: there are not an overwhelming number of ME/CFS experts, but neither are there an overwhelming number of experts in unexplained chronic fatigue, psychogenic models, or “other multi-symptom, complex disorders” as described in the Statement of Work. To our team, the key issue is bias.
excerpt:
The overall panel balance is 53% known and 47% unknown to the ME/CFS community. None of us think this is sufficient, but we do not agree on what the right split would be. Some of us think the panel should be 100% ME/CFS experts; others think the addition of at least one or two more experts would be appropriate.
Mary Dimmock has raised a very important point: in order to judge whether this panel is adequate, we have to think about the task. If this panel is going to create a case definition for the broader set of conditions that meet the various CFS criteria, then some might make the argument that this panel is appropriate. But if the panel is focused on the disease we described to the FDA in April, then Mary concludes that the panel needs more, and a broader cross-section, of ME/CFS experts and fewer psychologists. As Mary has reported, HHS and IOM have been vague in detailing which disease group is the focus of the panel.
We’re faced with a chicken-egg dilemma: identifying the disease focus should happen prior to the panel selection, but instead we have a panel with a seemingly vague task focus. This panel composition seems to hold a middle ground: there are not an overwhelming number of ME/CFS experts, but neither are there an overwhelming number of experts in unexplained chronic fatigue, psychogenic models, or “other multi-symptom, complex disorders” as described in the Statement of Work. To our team, the key issue is bias.